Whereas HMA monotherapy fails to eradicate leukemia stem cells [47], BCL-2 inhibition has been shown to selectively eradicate leukemia stem cells by suppressing oxidative phosphorylation [87], explaining the favorable clinical activity of the combination treatment of azacitidine and venetoclax in older AML patients [88]. This evidence concerns the gene BCL2 and acute myeloid leukemia.